Naproxen Krka (Naproxen Sodium)

Naproxen Krka, an NSAID, acts on inflammatory pathways to provide analgesic and antipyretic effects.

• Mild to moderate pain: alleviates headaches, dental pain, musculoskeletal aches, and postoperative discomfort.
• Rheumatoid arthritis: reduces joint inflammation, swelling, and stiffness, improving mobility.
• Osteoarthritis: diminishes chronic joint pain and inflammation associated with degenerative cartilage loss.
• Dysmenorrhea: eases menstrual cramps by decreasing uterine prostaglandin production.
• Gout flares: relieves acute gouty arthritis pain and swelling.

• Naproxen sodium reversibly inhibits cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, decreasing the conversion of arachidonic acid to prostaglandins and thromboxanes. This reduction in prostaglandin synthesis attenuates inflammation, pain signaling, and fever generation throughout the body. By blocking both isoforms, naproxen provides a balanced anti‑inflammatory effect while preserving some protective gastric prostaglandins compared with selective COX‑2 inhibitors. The drug’s plasma half‑life allows sustained COX inhibition over 12‑24 hours, supporting once‑ or twice‑daily dosing regimens.

Naproxen Krka may cause a range of adverse reactions, varying from mild and transient to serious but uncommon.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia, abdominal pain or heartburn that may resolve with food.
• Headache: mild to moderate intensity, often transient.
• Dizziness or vertigo: sensation of light‑headedness or imbalance.
• Mild skin reactions: rash, pruritus or localized erythema.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding: severe stomach or intestinal ulcers that can cause hematemesis or melena.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome, toxic epidermal necrolysis, or anaphylaxis.
• Renal impairment: acute kidney injury manifested by reduced urine output or elevated creatinine.

When prescribing or dispensing Naproxen Krka, consider the following precautions to minimize risk and ensure safe use.

• Cardiovascular risk: avoid in patients with uncontrolled hypertension or recent myocardial infarction.
• Gastrointestinal history: use with caution in individuals with a history of ulcers, bleeding, or chronic NSAID use.
• Renal function: monitor kidney function in patients with pre‑existing renal disease or dehydration.
• Concomitant anticoagulants: assess bleeding risk when combined with warfarin, aspirin, or other anticoagulants.
• Pregnancy and lactation: evaluate benefits versus risks; avoid in late pregnancy unless essential.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naproxen Krka can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of serious bleeding.
• Selective COX‑2 inhibitors (e.g., celecoxib): additive gastrointestinal toxicity.
• Corticosteroids (e.g., prednisone): heightened chance of ulceration and bleeding.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs (e.g., lisinopril, losartan): may reduce renal perfusion, especially in volume‑depleted patients.
• Diuretics (e.g., furosemide): potential for decreased renal function and electrolyte imbalance.
• Lithium: NSAIDs can raise lithium serum levels, risking toxicity.